Oncolytics Biotech Inc.
) reported positive preliminary results from the US phase II
trial (REO 020) evaluating the use of oncology candidate,
Reolysin in combination with
) Taxol (paclitaxel) and carboplatin, which are widely used
chemotherapy treatment. The phase II trial aims to assess the
safety and efficacy profile of Reolysin in patients suffering
from metastatic melanoma.
ANIKA THERAPEUT (ANIK): Free Stock Analysis
BRISTOL-MYERS (BMY): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ONCOLYTICS BIO (ONCY): Free Stock Analysis
To read this article on Zacks.com click here.
The study enrolled second-line or third-line metastatic malignant
melanoma patients. Patients for whom the standard first line
treatment was considered unsuitable were also enrolled. In the
first stage of the phase II trial, 3 of the 14 metastatic
melanoma patients demonstrated partial response (PR).
Additionally, 7 patients exhibited stable disease with a disease
control rate of 71.5%.
We are pleased with the preliminary results from the phase II
trial, which supports the candidate's progression into the second
stage. The primary endpoint of the phase II trial is to evaluate
the treatment regimen's anti-tumour effect. The secondary
endpoints include the evaluation of progression-free survival and
overall survival, disease control rate, safety and tolerability.
Investors have reacted positively to the encouraging preliminary
data on Reolysin.
We note Oncolytics Biotech is developing Reolysin as monotherapy
or in combination with chemotherapy and radiotherapy for several
oncology indications, including head and neck cancers (phase
III), pancreatic cancer (phase II) and non-small cell lung cancer
Oncolytics Biotech carries a Zacks Rank #2 (Buy). Right now,
Jazz Pharmaceuticals Public Limited Company
) look more attractive. Both stocks carry a Zacks Rank #1 (Strong